Home/Filings/4/0000899243-15-001088
4//SEC Filing

UNIVERSAL BIOSENSORS INC 4

Accession 0000899243-15-001088

CIK 0001279695operating

Filed

Jul 12, 8:00 PM ET

Accepted

Jul 13, 12:01 PM ET

Size

15.0 KB

Accession

0000899243-15-001088

Insider Transaction Report

Form 4
Period: 2015-07-09
Wright Paul
DirectorChief Executive Officer
Transactions
  • Award

    Common stock

    2015-07-09+4,3477,304 total
  • Award

    Stock Option (Right to Buy)

    2015-07-09+60,00060,000 total
    Exercise: $0.00Exp: 2022-01-29Common Stock (60,000 underlying)
Holdings
  • Common stock

    (indirect: By Trust)
    606,516
  • Stock Option (Right to Buy)

    Exercise: $0.00Exp: 2019-11-12Common Stock (37,500 underlying)
    37,500
  • Common stock

    (indirect: By P K W Super Fund)
    142,105
  • Stock Option (Right to Buy)

    Exercise: $0.00Exp: 2020-12-11Common Stock (60,000 underlying)
    60,000
  • Common stock

    (indirect: By Macqarie Super Fund Manager)
    44,666
  • Stock Option (Right to Buy)

    Exercise: $1.38Exp: 2018-02-23Common Stock (2,300,000 underlying)
    2,300,000
Footnotes (8)
  • [F1]The prices reported are stated in Australian dollars.
  • [F2]The reported securities are held in trust for the benefit of the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
  • [F3]The reported securities are held by the Macquarie Super Fund Manager in a pooled superannuation fund for the account of the Reporting Person.
  • [F4]The reported securities are held by the Macquarie Super Fund Manager in trust and for the account of the Reporting Person.
  • [F5]On December 12, 2013, the board of directors approved the grant of these options subject to shareholder approval. Such shareholder approval was received on June 12, 2014. The stock options vest and become exercisable in three equal tranches on 12/31/14, 12/31/15 and 12/31/16.
  • [F6]On November 13, 2012, the board of directors approved the grant of these options subject to shareholder approval. Such shareholder approval was received on May 16, 2013. The stock options vest and become exercisable in three equal tranches on 12/31/13, 12/31/14 and 12/31/15.
  • [F7]1,400,000 options vest in equal tranches over three years subject to continued employment at the time of vesting. 500,000 of the options vested upon the company entering into a material partnership/licensing agreement with Siemens Healthcare Diagnostics, Inc. on September 9, 2011. 400,000 options vest upon CE marketing or first regulatory approval in the United States of the final test to which the partnership/licensing arranagement relates, subject to continued employment at the time of vesting.
  • [F8]On January 30, 2015, the board of directors approved the grant of these options subject to shareholder approval. Such shareholder approval was received on July 9, 2015. The stock options vest and become exercisable in three equal tranches on 12/31/14, 12/31/15 and 12/31/16.

Issuer

UNIVERSAL BIOSENSORS INC

CIK 0001279695

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001279695

Filing Metadata

Form type
4
Filed
Jul 12, 8:00 PM ET
Accepted
Jul 13, 12:01 PM ET
Size
15.0 KB